TRIB (Trinity Biotech) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


TRIB Trinity Biotech PLC TRIB
20 GF Score
Price $0.33
GF Value $0.73
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Trinity Biotech Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Trinity Biotech's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

TRIB vs PMI, NXL, CSDX: Margin of Safety % (DCF Earnings Based) Comparison

For the Medical Devices subindustry, Trinity Biotech's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Trinity Biotech Margin of Safety % (DCF Earnings Based) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Trinity Biotech's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Trinity Biotech's Margin of Safety % (DCF Earnings Based) falls into.


TRIB
20GF Score
Trinity Biotech PLC TRIB
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Trinity Biotech (TRIB) Overvalued in 2026?

Based on GuruFocus' analysis, Trinity Biotech stock appears to be undervalued. The current stock price of $0.33 is trading 54.8% below its estimated GF Value™ of $0.73. GuruFocus considers Trinity Biotech to be Possible Value Trap.

Key valuation signals for TRIB:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $0.73 vs. price of $0.33 (54.8% below fair value)
  • GF Score™: 20/100 with 7 warning signs

No single metric tells the full story. See the TRIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Trinity Biotech Business Description

Address IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
20GF Score

Get the complete analysis for TRIB

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.33
Price
$0.73
GF Value